<DOC>
	<DOCNO>NCT01915940</DOCNO>
	<brief_summary>The objective Phase 2 study evaluate whether Bimatoprost Ocular Insert non-inferior timolol ophthalmic solution ( 0.5 % ) 12 week .</brief_summary>
	<brief_title>Bimatoprost Ocular Insert Compared Topical Timolol Solution Patients With Glaucoma Ocular Hypertension</brief_title>
	<detailed_description />
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Glaucoma</mesh_term>
	<mesh_term>Glaucoma , Open-Angle</mesh_term>
	<mesh_term>Ocular Hypertension</mesh_term>
	<mesh_term>Pharmaceutical Solutions</mesh_term>
	<mesh_term>Bimatoprost</mesh_term>
	<mesh_term>Timolol</mesh_term>
	<criteria>Key Written inform consent Primary openangle glaucoma ocular hypertension eye Bestcorrected distance vision 20/80 well Stable visual field corneal thickness 490620 micrometer Key Cuptodisc ratio great 0.8 significant risk angle closure due pupil dilation , define Shaffer classification less grade 2 base gonioscopy laser surgery glaucoma/ocular hypertension one eye within last 12 month past history corneal refractive surgery past history incisional surgery glaucoma time corneal abnormality would interfere tonometry reading current participation investigational drug device study participation study within 30 day screen Inability accurately evaluate retina</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>Glaucoma</keyword>
	<keyword>Primary Open-Angle Glaucoma</keyword>
	<keyword>Ocular Hypertension</keyword>
</DOC>